Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barlogie, Bart, Pineda-Roman, Mauricio, van Rhee, Frits, Haessler, Jeff, Anaissie, Elias, Hollmig, Klaus, Alsayed, Yazan, Waheed, Sarah, Petty, Nathan, Epstein, Joshua, Shaughnessy, John D., Tricot, Guido, Zangari, Maurizio, Zeldis, Jerome, Barer, Sol, Crowley, John
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2569166/
https://ncbi.nlm.nih.gov/pubmed/18492953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-03-145235
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados